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ABSTRACT 
OBJECTIVE - Heart failure is a prothrombotic state and it has been hypothesized that 
thrombosis and embolism cause non-fatal and fatal events in heart failure and reduced ejection 
fraction (HFrEF). We sought to determine the effect of anticoagulant therapy on clinical 
outcomes in patients with HFrEF who are in sinus rhythm.  
 
METHODS - We conducted an updated systematic review and meta-analysis to examine the 
effect of anticoagulation therapy in patients with HFrEF in sinus rhythm. Our analysis 
compared patients randomized to anticoagulant therapy with those randomized to antiplatelet 
therapy, placebo or control, and examined the endpoints of all-cause mortality, 
(re)hospitalization for worsening heart failure, non-fatal myocardial infarction, non-fatal stroke 
of any aetiology, and major haemorrhage.  
 
RESULTS - Five trials were identified that met the prespecified search criteria. Compared with 
control therapy, anticoagulant treatment did not reduce all-cause mortality (RR 0.99, 95%CI 
0.90-1.08), (re)hospitalisation for heart failure (RR 0.97, 95%CI 0.82-1.13) or non-fatal 
myocardial infarction (RR 0.92, 95%CI 0.75-1.13). Anticoagulation did reduce the rate of non-
fatal stroke (RR 0.63, 95%CI 0.49-0.81, p=0.001), but this was offset by an increase in the 
incidence of major haemorrhage (RR 1.88, 95%CI 1.49-2.38, p=0.001), but this was offset by 
an increase in the incidence of major haemorrhage (RR 1.88, 95%CI 1.49-2.38, p <0.001). 
 
CONCLUSIONS - Our meta-analysis provides evidence to oppose the hypothesis that 
thrombosis or embolism plays an important role in the morbidity and mortality associated with 
HFrEF, with the exception of stroke-related morbidity. 
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KEY QUESTIONS 
 
 
What is already known about this subject? 
 
A benefit of anticoagulation in patients with heart failure in sinus rhythm has not been 
established, despite the fact that heart failure is a prothrombotic syndrome. Older trials in these 
patients suggested that warfarin reduced stroke at the expense of an increased haemorrhagic 
risk, but without a discernible effect on all-cause mortality.  
 
 
What does this study add? 
 
Our meta-analysis and critical review includes the COMMANDER-HF trial, which more than 
doubles the number of patients available for analysis. Our results confirm that anticoagulation 
does not reduce all-cause mortality, readmission for heart failure or myocardial infarction in 
patients with heart failure and sinus rhythm. From a pathophysiological perspective, our 
analysis provides evidence to oppose the hypothesis that unidentified thrombosis or embolism 
commonly underlie the morbidity and mortality associated with heart failure. 
 
How might this impact on clinical practice? 
 
This meta-analysis strengthens current guideline recommendations that heart failure with 
reduced ejection fraction is not by itself an indication for anticoagulation.   
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INTRODUCTION 
There has been a long-standing hypothesis that both arterial and venous thrombosis and 
embolism might contribute to fatal as well as non-fatal events in patients with heart failure 
even when in sinus rhythm. This hypothesis reflected the view that heart failure is a 
prothrombotic state due to endothelial dysfunction, inflammation and increased thrombin 
production.[1-5] The logical proof of this hypothesis would be demonstration of reduced 
morbidity and mortality with an oral anticoagulant. Crucially, any such benefit must clearly 
outweigh the risk of clinically important bleeding. Although trials have been conducted to try 
and determine the balance between the benefit and risk of anticoagulation in heart failure (with 
reduced ejection fraction, in all cases), most have been insufficiently powered to give a 
definitive answer to this question. The largest, the Warfarin versus Aspirin in Reduced Cardiac 
Ejection Fraction (WARCEF) trial, did suggest potential benefit of warfarin but at the expense 
of unacceptable bleeding risk. Consequently, the recent completion of the Study to Assess the 
Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction, 
or Stroke in Participants with Heart Failure and Coronary Artery Disease Following an Episode 
of Decompensated Heart Failure (COMMANDER-HF) is a critical additional (and probably 
final) contribution to the evidence base related to this question. The non-vitamin K oral 
anticoagulants (NOACs) have proven to be at least as effective as warfarin and safer, in terms 
of major bleeding, even in patients with heart failure,[6] and this trial had the potential to 
replicate the benefit of anticoagulation seen in WARCEF with acceptable safety. 
Accordingly, we conducted a meta-analysis of all relevant trials to determine the effect of 
anticoagulant treatment on death and other major clinical events in patients with heart failure 
and reduced ejection fraction (HFrEF) who were not in atrial fibrillation. 
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METHODS 
 
Selection of outcomes 
The main outcomes of interest were (1) death from any cause; (2) (re)hospitalisation due to 
worsening heart failure; (3) non-fatal stroke of any cause; (4) major haemorrhage; (5) non-fatal 
myocardial infarction. 
 
Search strategy and study selection 
We systematically identified published randomised controlled trials (RCTs) testing oral 
anticoagulation therapy against oral antiplatelet therapy (ATT) and/or placebo therapy and/or 
no therapy (collectively referred to from hereon in as control therapy), in adult patients with 
heart failure who were in sinus rhythm. Since the subject of interest was chronic heart failure, 
studies were excluded if they involved patients who were in hospital with acute heart failure, 
or in the acute phase of recovery following a myocardial infarction. Eligible studies were 
required to report at least one of the outcome measures detailed above. We performed searches 
of Medline (via PubMed) and the Cochrane Controlled Register of Trials (CENTRAL) (from 
1966 to August 2018), using search terms including “anticoagulant”, “warfarin”, “apixaban”, 
“rivaroxaban”, “dabigatran”, “edoxaban”, “heart failure” and “left ventricular systolic 
dysfunction” as search terms in the abstract, MeSH subject heading, keyword heading or title 
fields. Prospective RCTs conducted in adults that were published in English were considered. 
Studies identified via conference presentation and bibliographic search were also considered 
for inclusion. Unpublished data were not sought. We restricted our search to RCTs enrolling 
>100 patients. Additional information regarding our method of study selection is presented in 
the supplementary appendix, along with model search strategies employed. Included trials were 
assessed for bias using the Cochrane Risk of Bias Tool (see supplementary appendix). A 
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Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart 
detailing the selection process is presented in Figure 1. No protocol is available. 
FIGURE 1 HERE [PRISMA] 
 
Data extraction 
Two authors (SB and RR) independently assessed trial eligibility and extracted data from 
included trials. Data in relation to the main outcomes of interest (1 to 5, detailed above) were 
collected.  Differentiation between ischaemic or haemorrhagic stroke was not made 
consistently across studies, and for this reason all strokes were combined in a single efficacy 
outcome.  
 
Statistical analysis 
We utilised summary statistics from the individual trials because patient-level data were not 
available. Hazard ratios and 95% confidence intervals (CIs) from original trial results papers 
were used as the principal summary measures where available. Where hazard ratios were not 
available, rate ratios were used instead, and where neither of these measures were stated, risk 
ratios were generated using available data. These metrics were considered equivalent and are 
henceforth referred to identically as risk ratios (RRs). Single-study estimates were combined 
using inverse variance-weighted averages of logarithmic RRs in both fixed- and random-
effects analysis. Heterogeneity between studies was assessed using the I2 statistic and 
Cochran’s Q statistic. The I2 statistic has limited power when applied to a small number of 
studies; we considered the presence of heterogeneity when I2 exceeded 50%, wherein we 
planned to utilise a random-effect model. We considered heterogeneity to be present at a 
significance level of 10% for Cochran’s Q statistic. The fixed-effect model was otherwise 
employed preferentially. Where either the fixed-effect or random-effect model was used, the 
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result derived from the alternative model is additionally reported in the supplementary 
appendix. A weighting was derived from the number of events that occurred in each study. We 
performed pre-specified sensitivity analyses for each outcome measure to assess the 
contribution of any single trial to the pooled estimate by recalculating the pooled estimate after 
excluding single trials one by one. Publication bias was sought using Eggers’s test for small-
study effects. Analyses were performed using Stata version 14 (StataCorp, College Station, 
Texas).  
 
RESULTS 
Characteristics of studies included in meta-analysis 
A total of 1040 titles were screened. Of these, 1035 were excluded (see Figure 1). Five RCTs 
were identified that met the pre-specified search criteria. These were: (1) the Warfarin/Aspirin 
Study in Heart failure (WASH) trial;[7] (2) the HEart failure Long term Antithrombotic Study 
(HELAS);[8] (3)  the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) 
trial;[9] (4) WARCEF;[10] and (5) COMMANDER-HF.[11] In total these trials contributed 
up to 9390 patients to our meta-analysis, more than half of whom came from the recent 
COMMANDER-HF trial.  
 
The design and population characteristics of these trials are summarised in Table 1. Event rates 
from individual trials for the clinical outcome measures evaluated in this meta-analysis are 
presented in Table 2.  An assessment of the risk of bias among these trials is presented in the 
supplementary appendix. In summary, all individual trials were deemed either of low risk 
(WARCEF and COMMANDER-HF) or unclear risk (WASH, HELAS and WATCH), with 
none deemed high risk; bias across studies was deemed either low or unclear risk. WASH 
utilised a Prospective Randomized Open-label Blinded End point (PROBE) trial design, 
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randomising patients to open-label anticoagulation with warfarin, antiplatelet therapy with 
aspirin, or no therapy. For the purposes of this meta-analysis, we compared patients randomised 
to anticoagulation in WASH with those patients receiving ATT or no therapy. A small number 
of patients in WASH were in atrial fibrillation (AF) at enrolment or developed it during the 
trial. Where data were available for patients in sinus rhythm exclusively, these were used 
preferentially. WATCH randomised patients to open-label anticoagulation (warfarin) or one of 
aspirin or clopidogrel, which were provided in a double blind, double-dummy design. We 
compared patients randomised to anticoagulation in WATCH with patients assigned to any 
antiplatelet agent. HELAS was a double-blind trial involving stratification of treatment 
assignment according to aetiology of heart failure. Patients with HFrEF of ischaemic aetiology 
were randomised to receive either warfarin or aspirin; patients with idiopathic dilated 
cardiomyopathy were randomised to receive either warfarin or placebo. We compared all 
patients receiving warfarin to a control arm including all patients randomised to either aspirin 
or placebo. WARCEF and COMMANDER-HF were both double-blind RCTs involving 
random allocation to either anticoagulation (warfarin in WARCEF and rivaroxaban in 
COMMANDER-HF) or placebo. All studies employed satisfactory randomisation.  
 10 
Effect of anticoagulation therapy on all-cause mortality 
Among the 4361 patients randomized to anticoagulation and 5004 patients randomized to 
control therapy, there were 946 and 1076 all-cause deaths respectively. Compared with the 
control group, anticoagulation was not associated with a reduction in all-cause mortality (RR 
0.99, 95%CI 0.90-1.08). The point estimates were similar in all five RCTs (RR ranging from 
0.94 to 1.03) indicating a consistent lack of effect across the trials. In a sensitivity analysis, 
there was no significant difference in the effect on all-cause mortality after the removal of any 
single study from the pooled analysis. We did not detect evidence of significant heterogeneity 
between the trials (I2 statistic = 0%; Cochran’s Q = 0.40; p = 0.98) 
FIGURE 2 HERE 
 
 
Effect of anticoagulation therapy on (re)hospitalisation for heart failure 
The effect of anticoagulation therapy was assessed using a random-effects model because of 
the likelihood of heterogeneity between the studies (I2 = 52%; Cochran’s Q = 8.41; p = 0.078). 
Among 4370 patients randomized to anticoagulation and 5020 patients randomized to control 
therapy, (re)hospitalisation for worsening heart failure occurred in 1040 and 1164 patients 
respectively. Compared with the control group, anticoagulation was not associated with a 
significant reduction in this outcome (RR 0.97, 95%CI 0.82-1.13). The magnitude of treatment 
effect failed to cross unity in any individual RCT, although there was a trend towards reduced 
rehospitalisation for heart failure with anticoagulation when compared to aspirin or clopidogrel 
in WATCH (RR 0.81, 95%CI 0.65-1.01) and a trend towards increased rehospitalisation with 
anticoagulation compared to aspirin in WARCEF (RR 1.21, 95%CI 1.00-1.47). Sensitivity 
analysis demonstrated no significant difference in the effect on (re)hospitalisation for heart 
failure after the removal of any single study from the pooled analysis. 
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FIGURE 3 HERE 
 
Effect of anticoagulation therapy on non-fatal stroke from any cause 
Stroke of ischaemic aetiology was not clearly defined/available for WASH, HELAS or 
COMMANDER-HF. Consequently, stroke of any cause was used in this analysis. Among 4361 
patients randomized to anticoagulation and 5004 patients randomized to control therapy, non-
fatal stroke occurred in 94 and 163 patients respectively. Compared with the control group, 
there was a significant reduction in stroke with anticoagulation compared to control (RR 0.63, 
95%CI 0.49-0.81, p = 0.001). This effect appears consistent across all five RCTs, although 
only WARCEF and COMMANDER-HF (which together contribute >75% of the patients in 
this meta-analysis) were individually statistically significant. There was no suggestion of 
publication bias when the RCTs were examined using Egger’s test for small-study effects (p = 
0.63). It should be noted that the power to detect publication bias using Egger’s test is limited 
when only a small number of studies are available for analysis, such as is the case here. 
Sensitivity analysis demonstrated no significant difference in the effect on stroke after the 
removal of any single study from the pooled analysis. We did not detect evidence of significant 
heterogeneity between the trials (I2 statistic = 0%; Cochran’s Q = 0.45; p = 0.98). 
FIGURE 4 HERE 
 
 
Effect of anticoagulation therapy on non-fatal MI 
Among 4361 patients randomized to anticoagulation and 5004 patients randomized to control 
therapy, non-fatal MI occurred in 150 and 184 patients respectively. Compared with the control 
group, anticoagulation therapy did not reduce the risk of non-fatal MI (RR 0.92, 95%CI 0.75-
1.13). There was no suggestion of benefit from anticoagulation compared to the control group 
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in any individual trial. Sensitivity analysis demonstrated no significant difference in the effect 
on non-fatal MI after the removal of any single study from the pooled analysis. We did not 
detect evidence of significant heterogeneity between the trials (I2 statistic = 36%; Cochran’s Q 
= 6.28; p = 0.179). 
FIGURE 5 HERE 
 
 
Effect of anticoagulation therapy on major haemorrhage 
Among 4370 patients randomized to anticoagulation and 5020 patients randomized to control 
therapy, major haemorrhage occurred in 187 and 112 patients respectively. There was a 
significant increase in the risk of a major haemorrhage with anticoagulant therapy, compared 
with control therapy (RR 1.88, 95%CI 1.49-2.38, p <0.001). This effect was consistent across 
the three largest trials (WATCH, WARCEF and COMMANDER-HF), which together 
contributed >90% of events in the anticoagulation group. Sensitivity analysis demonstrated no 
significant difference in the effect on major haemorrhage after the removal of any single study 
from the pooled analysis. We did not detect evidence of significant heterogeneity between the 
trials (I2 statistic = 16%; Cochran’s Q = 4.74; p = 0.315). 
 
FIGURE 6 HERE 
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DISCUSSION 
Implicit in the “thrombosis/embolism” hypothesis of heart failure is the notion that many such 
events must be unidentified, because the rates of recognised MI and stroke in patients with this 
syndrome are low compared with the dominant drivers of morbidity and mortality which are 
cardiovascular death and heart failure hospitalisation.[1-5] However, it is plausible that 
coronary thrombotic occlusion might cause sudden cardiac death and even pump failure death 
in patients with electrically unstable and already failing left ventricles. Alternatively, non-fatal 
coronary thrombotic occlusion could lead to admission with worsening heart failure associated 
with a raised troponin. Similarly, embolization of cardiac thrombus, or even thrombosis 
resulting from cerebral hypoperfusion, might lead to fatal stroke classified as a “sudden death”. 
Lastly, venous thromboembolism could also lead to sudden death or be an unrecognized cause 
of presentation with worsening dyspnoea or the development of pulmonary hypertension in 
patients with heart failure.  
Accepting the assumption that anticoagulation is effective at preventing thrombosis and 
embolism, the completely neutral effect of anticoagulant therapy on both death and heart failure 
hospitalisation demonstrated in our meta-analysis suggests that unidentified thrombosis or 
embolism do not, after all, play an important role in the pathogenesis of the major causes of 
mortality in HFrEF.  
In terms of morbidity resulting from identified thrombotic/embolic events - namely stroke and 
MI - there is somewhat more to say. One unequivocal finding of this meta-analysis is that 
anticoagulant therapy decreases the incidence of stroke with a substantial relative risk reduction 
of 37% when compared to control therapy. Whether this reflects a benefit in patients with 
clinically unidentified atrial fibrillation or new-onset atrial fibrillation (which is associated with 
a very high risk of stroke in HFrEF [17]), prevention of cardiac embolism even in sinus rhythm, 
or cerebral arterial thrombosis is unknown. Because the incidence of stroke in the trials 
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conducted was low, large numbers of patients had to be exposed to anticoagulant therapy to 
prevent one stroke; consequently, the beneficial effect on stroke was matched by similar harm 
related to bleeding, even with a NOAC. Specifically, in COMMANDER-HF, rivaroxaban 
reduced the risk of stroke from a rate of 3.0 to 2.0 events per 100 person-years which was 
counterbalanced by an increase in the risk of major haemorrhage from 2.0 to 3.3 events per 
100 person-years (although it should be noted that most patients in both treatment groups were 
receiving concomitant anti-platelet therapy). Clearly, the totality of evidence does not support 
the general use of anticoagulation in patients with HFrEF to reduce the risk of stroke (or any 
other event). It may be possible, using risk scores, to identify a subset of patients with HFrEF 
(and heart failure with preserved ejection fraction), not in atrial fibrillation, who are at a 
substantially increased risk of stroke.[18-20] Further refinement of stroke risk prediction, 
perhaps using biomarkers,[21-22] seems a worthwhile effort, given the possibility of targeting 
an undoubtedly effective treatment at the prevention of such a devastating cardiovascular 
complication. Selective use of anticoagulation therapy in such patients might have a more 
favourable benefit-to-risk profile but this needs to be tested prospectively in clinical trials. 
In contrast to the reduction in stroke with anticoagulation, however, it was not possible to 
demonstrate a benefit of anticoagulant therapy on clinically recognised acute coronary events, 
even despite the substantial cumulative number of MIs in this meta-analysis. In this context, 
examination of the COMMANDER-HF trial is instructive. Participants in the trial were 
required to have coronary artery disease (CAD), based on the supposition both that thrombin 
plays a fundamental role in deleterious pathophysiological processes which occur in patients 
with CAD following a recent heart failure decompensation, and that rivaroxaban - a specific 
inhibitor of activated Factor Xa which interrupts thrombin production – would be more 
efficacious in this setting than conventional vitamin K antagonists. Patients were also required 
both to have experienced a recent exacerbation of heart failure symptoms, and to have an 
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elevated natriuretic peptide concentration, further enriching the risk profile of the trial cohort. 
Despite these measures, the results of COMMANDER-HF were similar to those of the 
preceding RCTs that trialled warfarin in populations with HFrEF of mixed ischaemic and non-
ischaemic aetiology, in that anticoagulation did not result in a lower rate of MI. This may seem 
a surprising finding, given the clear evidence from older trials with warfarin, and two more 
recent trials with NOACs, that anticoagulants, both alone and in combination with antiplatelet 
therapy, can reduce the risk of MI.[12-15] There are several potential explanations for this 
anomaly. Most likely is the probability that many MIs in patients with HFrEF are “type 2” 
events, caused by myocardial ischaemia due to increased oxygen demand (e.g. due to 
tachycardia, bradycardia, arrhythmias, myocardial hypertrophy, increased wall stress), 
decreased supply (e.g. due to anaemia, increased left ventricular end-diastolic pressure, 
microvascular dysfunction, hypotension, hypoxaemia) or both.[16] Where MI does play a 
precipitant role in morbidity and mortality in HFrEF, the pathogenesis of “type 2” events is 
unlikely to be altered by anticoagulation. Less likely is the possibility that coronary thrombus 
in heart failure is more resistant to anticoagulant therapy than in other conditions – however 
the lack of treatment effect in a risk-enriched population, and this despite the therapeutic 
potency of the drug employed, argues against this. Indeed, such was the targeted design of 
COMMANDER-HF – wherein rivaroxaban seemed ideally suited to preventing coronary 
thrombosis/emboli in a population at high risk of these events – that it is improbable that this 
hypothesis will, or indeed should, be retested in further RCTs. Thus COMMANDER-HF likely 
represents the final instalment in this suite of trials. 
 
The evidence reviewed here pertains to patients with HFrEF and the potential value of 
anticoagulant therapy in patients with HFpEF (but without atrial fibrillation) has not been 
studied. However, it is difficult to imagine the results would be different, especially as 
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underlying coronary artery disease is less common in HFpEF than HFrEF (meaning the risk of 
myocardial infarction is lower) and because the risk of embolic stroke in heart failure may be 
greatest in patients with severely reduced ejection fraction.[23-24] 
 
In summary, in this comprehensive meta-analysis of 5 prospective randomised controlled trials 
including over 9000 patients, anticoagulant therapy was unequivocally demonstrated to have 
no effect on mortality, heart failure hospitalisation or myocardial infarction when compared to 
control therapy. Conversely, there was equally clear evidence that anticoagulant therapy 
reduced the risk of stroke compared to control therapy, but this benefit was completely offset 
by a similar increase in risk of absolute rates of major bleeding, even with a NOAC. In clinical 
terms, any future efforts to establish a role for anticoagulant therapy in heart failure should 
focus on targeted treatment of patients at high risk of stroke where the benefit-to-risk balance 
might be more favourable. From a mechanistic perspective, these trials suggest that, excepting 
clinically recognised stroke, thrombosis and embolism that are amenable to treatment are 
unlikely to play a major role in the pathogenesis of major morbidity or mortality in heart failure. 
 
Study limitations 
We conducted a meta-analysis of large randomized trials, with this method of analysis carrying 
limitations that merit consideration. The main limitation was that our analysis using trial-level 
data rather than patient-level data, which were unavailable. This limits the possibility of 
adjustment for individual patient characteristics. We pooled the effects of two different types 
of anticoagulant therapy (i.e. a vitamin K antagonist (warfarin) and non-vitamin K antagonists) 
but assumed a class ‘anticoagulant’ effect. In addition, the intensity of warfarin-induced 
anticoagulation varied between the trials using that agent. It is possible that these differences 
may have introduced heterogeneity into the analysis, although this is more likely to have 
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influenced the adverse-effect profile (particularly bleeding rates), rather than efficacy. Other 
potential sources of heterogeneity include differences between the trials in relation to patient 
inclusion and exclusion criteria, and geographical location (see Table 1). It was not possible to 
differentiate between ischaemic and haemorrhagic stroke consistently across the included 
trials. At a study level, one limitation is that a small number of patients in WARCEF and 
WASH had previously experienced atrial fibrillation or developed this condition during the 
trial. Study level limitations relating to bias are detailed in Appendix 2. As stated above, the 
utility of Egger’s test to detect publication bias is limited when only a small number of studies 
are available for analysis. 
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Table 1: Baseline characteristics of patients with heart failure in sinus rhythm randomised to anticoagulation therapy or control 
 
 
Characteristic     WASH [7] HELAS [8] WATCH [9] WARCEF [10] COMMANDER-HF [11] 
Year of publication     2004 2006 2009 2012 2018 
Study design     
Open-label, randomised, 
controlled trial 
Double-blind, 
randomised, placebo-
controlled trial 
Double-blind, randomised 
trial. Double-dummy 
controlled for ATT, or 
open-label warfarin 
Double-blind, 
randomised, double-
dummy controlled trial 
Double-blind, 
randomised, placebo-
controlled trial 
Main inclusion 
criteria     
HF requiring diuretic HF (NYHA II - IV) 
i) Symptomatic HF 
ii) Sinus rhythm 
iii) Diuretic + ACE-
inhibitor ≥60 days 
i) HF (NYHA I - IV) 
ii) Sinus rhythm 
i) HF ≥3 months duration 
ii) CAD 
iii) recent WHF 
iv) elevated natriuretic 
peptide concentration* 
LVEF inclusion criterion   ≤ 35% < 35% ≤ 35% ≤ 35% ≤ 40% 
Location     
US & UK 
Greece, Cyprus, 
Yugoslavia, 
Romania, Bulgaria, Poland 
and Georgia 
US, UK & Canada 
North America, Europe & 
Argentina 
Europe, North America, 
Latin America, Asia-
Pacific & South Africa 
No. randomised     279 197 1587 2305 5022 
Therapies evaluated     
Warfarin vs aspirin vs no 
ATT 
Warfarin vs aspirin vs 
placebo 
Warfarin vs aspirin vs 
clopidogrel 
Warfarin vs aspirin Rivaroxaban vs placebo 
Target INR     2.0 - 3.0 2.0 - 3.0 2.5 - 3.0 § 2.0 - 3.5 N/A 
Aspirin dose     300mg/day 325mg/day 162mg/day 325mg/day N/A 
Other antiplatelet 
dose 
    N/A N/A Clopidogrel 75mg/day N/A N/A 
        
Follow-up, mean (SD), mo   27 (1) 19 (NR) 23 (NR) 42 (22) 21 (NR) ◊ 
Demographics        
 Age, mean (SD), y   63 (NR) 55 - 62 63 (11) 61 (11) 66 (10) 
 Female, %   26 15 15 20 23 
 Race or ethnic group             
   White, % NR NR 77 75 82 
   Black, % NR NR 13 14 1 
   Other, % NR NR 10 10 17 
 BMI, mean (SD), kg/m2   NR NR NR 29 (6) 28 (5) 
 NYHA functional class             
   NYHA class I, % NR 0 0 14 3 
   NYHA class II, % NR NR 44 55 44 
   NYHA class III, % 27% NR 54 30 49 
   NYHA class IV, % 2% NR 2 1 4 
 Smoking status             
   Current, % NR 49 17 18 NR 
   Former, % NR NR 60 51 NR 
   Never smoked, % NR NR 23 31 NR 
 Hypertension   34 37 48 61 75 
 Diabetes mellitus   20 21 34 31 41 
 Atrial fibrillation   6 0 0 4 0 
 Myocardial infarction   46 49 58 48 76 
 Ischaemic cardiomyopathy   60 58 73 43 NR 
 Pulmonary or other embolism   NR 0 NR 2% NR 
 Prior stroke or TIA   NR 0 5 13 9 
 
Blood pressure at baseline 
SBP, mean (SD), 
mmHg  
126 (NR) NR 119 (18) 124 (19) NR 
 
  
DBP, mean (SD), 
mmHg  
77 (NR) NR NR 74 (11) NR 
  LVEF, mean (SD), %   NR ‖ 27 - 29 25 (6) 25 (8) 34 @ 
Medications at baseline, %        
 Aspirin†   48 NR NR 59 93 
 Other antiplatelet†   NR NR NR 8 40 
 Warfarin / other oral anticoagulant* 5 NR 1 8 0 
 ACE inhibitor / ARB   91 61 97 98 93 
 Beta-blocker   11 12 70 90 92 
 MRA   NR NR 28 60 77 
 Nitrate   NR 32 NR 24 20 
 Diuretic   96 #  59 99 81 96 
  Statin   NR NR NR 83 NR 
Device at baseline, 
% 
    
          
 Pacemaker   NR NR NR 12 4 
 ICD   NR NR NR 18 9 
  CRT   NR NR NR NR 2 
Design Primary endpoint   
Composite outcome 
of death, nonfatal MI, and 
nonfatal 
stroke. 
Composite of non-fatal 
stroke, peripheral or 
pulmonary embolism, 
MI, re-hospitalisation, 
WHF, or ACM; 
Composite of ACM, 
nonfatal MI and nonfatal 
stroke 
Time to first event in a 
composite end point of 
ischemic stroke, 
intracerebral 
haemorrhage, or ACM 
Composite of ACM, 
nonfatal MI and nonfatal 
stroke 
Internal validity          
 INR achieved in warfarin group   
Mean INR was 2.3 after 
excluding patients who 
discontinued treatment. 
NR 
Median INR was 2.5; 
70% of actual INRs were 
2.0 - 3.5 
After initial 6-week 
titration phase, mean INR 
was 2.6 +/- 0.9 ^ 
N/A 
 Follow-up, %   NR NR 94.4 98.5 99.8 
 Crossovers to A/C, % (No.)   NR Δ NR NR ¶ NR ‡ NR 
 
Crossovers to control % (No.)   NR Δ NR NR ¶ 
34% of total follow-up 
time ‡ 
28 
  Blinded endpoint committee   Yes NR Yes Yes No $ 
 
Abbreviations: ACE, angiotensin converting enzyme; ACM, all-cause mortality; ATT, antiplatelet therapy; CAD, coronary artery disease; HF, heart failure; MI, myocardial infarction; MRA, mineralocorticoid receptor 
antagonist; UK, United Kingdom; US, United States; WHF, worsening heart failure 
 
* After the enrolment of 1155 patients (23.0%), a protocol amendment required patients to also have a plasma concentration of brain natriuretic peptide (BNP) ≥200 pg/ml or N-terminal pro–brain natriuretic 
peptide (NT-proBNP) ≥800 pg/ml measured at any time during the screening period before randomization 
 
† Data on aspirin and other antiplatelet agents and warfarin or other oral anticoagulants are for the use of these medications before the patients underwent randomization 
 
‡ Patients in the warfarin group did not receive the randomly assigned medication (and instead received open-label therapy) for 34% of the total follow-up time, and patients in the aspirin group did not receive 
the assigned medication for 32% of the time 
 
§ INR of 2.0 - 3.5 designated acceptable 
 
‖ Mean fractional shortening = 16% 
 
¶ Crossover rates unknown. Number of patients discontinuing study drug were 100 in aspirin group and 110 in warfarin groups respectively. 
 
# Only patients prescribed a loop diuretic included 
 
^ 70.4% of measurements falling within the acceptable range (2.0 to 3.5), 20.3% falling below 2.0, and 9.3% falling above 3.5. The median INR was 2.5. 
 
Δ At 12 months, among patients initially assigned to aspirin or no ATT, 88% and 79% remained taking aspirin and without ATT respectively. Of those assigned to warfarin, 75% remained on warfarin at 12 months. 
 
◊ Median (cf mean) 
 
$ Outcome events reported by investigators and not independently adjudicated 
 
Table 2: Reported clinical events and event rates 
 
 
  All-cause mortality 
  
Anticoagulation  Control arm 
Trial  Participants Events 
Event rate (per 100 
person years) 
 
Participants Events 
Event rate (per 100 
person years) 
WASH  80 22 NR  174 48 NR 
HELAS  92 13 13.3 (d); 3 (e)  105 15 9.6 (f); 8.9 (g) 
WATCH  540 92 NR  1047 190 NR 
WARCEF  1142 275 6.6 (c)  1163 272 6.5 (c) 
COMMANDER  2507 546 11.4  2515 556 11.6 
         
         
  Rehospitalisation for heart failure 
  
Anticoagulation  Control arm 
Trial  Participants Events 
Event rate (per 100 
person years) 
 
Participants Events 
Event rate (per 100 
person years) 
WASH  89 18 20  190 50 17 (a); 29 (b) 
HELAS  92 5 2.4 (d); 4.4 (e)   105 7 3.2 (f); 5.9 (g) 
WATCH  540 89 NR  1047 213 NR 
WARCEF  1142 239 6.8  1163 203 5.7 
COMMANDER  2507 689 17.2  2515 691 17.5 
         
         
  Non-fatal stroke 
  
Anticoagulation  Control arm 
Trial  Participants Events 
Event rate (per 100 
person years) 
 
Participants Events 
Event rate (per 100 
person years) 
WASH  80 0 NR  174 3 NR 
HELAS  92 2 2.4 (d); 0 (e)  105 3 2.1 (f); 1.5 (g) 
WATCH  540 7 NR  1047 24 1.0 (h) 
WARCEF  1142 34 NR  1163 57 NR 
COMMANDER  2507 51 1.1  2515 76 1.6 
         
         
  Non-fatal MI 
  
Anticoagulation  Control arm 
Trial  Participants Events 
Event rate (per 100 
person years) 
 
Participants Events 
Event rate (per 100 
person years) 
WASH  80 1 NR  174 8 NR 
HELAS  92 2 1.2 (d); 1.5 (e)  105 0 0 
WATCH  540 21 NR  1047 27 NR 
WARCEF  1142 28 0.8  1163 31 0.9 
COMMANDER  2507 98 2.1  2515 118 2.5 
         
         
  Major haemorrhage 
  
Anticoagulation  Control arm 
Trial  Participants Events 
Event rate (per 100 
person years) 
 
Participants Events 
Event rate (per 100 
person years) 
WASH  89 4 NR  190 1 NR 
HELAS  92 7 4.8 (d); 4.4 (e)  105 0 0 
WATCH  540 28 NR  1047 30 NR 
WARCEF  1142 66 NR  1163 31 NR 
COMMANDER  2499 82 2.0  2509 50 1.2 
 
 
NR = not reported       
       
(a) Patients randomised to no antithrombotic therapy in WASH   
(b) Patients randomised to aspirin in WASH    
 
(c) Reported rate is for deaths as a component of the composite primary outcome measure, thus excluding 7 deaths due to 
haemorrhage; the rate for total mortality was not reported 
(d) Patients with ischaemic cardiomyopathy randomised to warfarin   
(e) Patients with dilated cardiomyopathy randomised to warfarin   
(f) Patients with ischaemic cardiomyopathy randomised to aspirin   
(g) Patients with dilated cardiomyopathy randomised to placebo   
(h) For combination of aspirin and clopidogrel arms in WATCH; this figure may include fatal strokes 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 
 
For more information, visit www.prisma-statement.org. 
 
Figure 1 - PRISMA flow diagram of selection process for 
included studies 
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